A Chinese biotech company, Ascletis, has just submitted two Investigational New Drug (IND) applications to the US FDA for the treatment of obesity.
A New Approach to Weight Management
Ascletis is seeking approval for two novel injectable treatments, ASC36 and ASC36_35 FDC, which represent a fresh approach to managing obesity. The company’s peptide-based therapies target specific receptors in the body that play a crucial role in appetite regulation and glucose metabolism.
How It Works
ASC36 is a once-monthly injection that works by activating amylin receptors in the brain, which helps to suppress appetite and reduce food cravings. This receptor agonist has been shown to induce significant weight loss in clinical trials. ASC36_35 FDC, on the other hand, is a co-formulation of ASC36 and another peptide, ASC35, which is a dual agonist of GLP-1R and GIPR receptors. By targeting these receptors, ASC36_35 FDC aims to stimulate insulin secretion and improve glucose metabolism, further contributing to weight loss.
What This Means
Ascletis’ submissions to the FDA mark a significant development in the obesity treatment space. If approved, these new therapies could provide patients with a safer and more effective alternative to existing weight loss treatments. The success of these treatments could also pave the way for the development of more innovative therapies targeting various metabolic disorders.
The use of peptide-based therapies like ASC36 and ASC36_35 FDC also highlights the growing importance of AI-driven drug discovery in the biotech industry. By leveraging machine learning algorithms and computational models, researchers can design and develop novel molecules that interact with specific biological targets, leading to the creation of more effective and targeted treatments.
